Richard A. Fair - 15 Aug 2022 Form 4 Insider Report for BELLICUM PHARMACEUTICALS, INC

Reporting relationship: President and CEO, Director
Issuer ticker: N/A
Reported as of: 15 Aug 2022
Net transaction value: +$576,000
SEC form: 4
Accepted by SEC: 16 Aug 2022, 17:04:29 UTC
Prior SEC filing: 18 Aug 2021
Next SEC filing: 12 Dec 2025
Source filing: View source filing
Reporting owner signature: /s/ Richard A. Fair

Key filing fact

Richard A. Fair filed Form 4 for BELLICUM PHARMACEUTICALS, INC on 16 Aug 2022.

Key facts

This page summarizes Richard A. Fair's Form 4 filing for BELLICUM PHARMACEUTICALS, INC.
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Aug 2022, 17:04.

Change

Previous filing in this sequence was filed on 18 Aug 2021.
Current net transaction value: +$576,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

BLCM transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $576,000
Shares: +400,000
Change %
Price: $1.44
Shares after: 400,000
Date: 15 Aug 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 400,000
Exercise price: $1.44
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

One-third (1/3rd) of the shares subject to the option will vest on the one-year anniversary on August 16, 2023, and the remaining shares will vest in twenty-four (24) equal monthly installments thereafter.